Stifel Nicolaus restated their buy rating on shares of Danaher (NYSE:DHR) in a report published on Friday. They currently have a $110.00 price objective on the conglomerate’s stock.

A number of other equities research analysts also recently weighed in on DHR. Goldman Sachs Group reissued a neutral rating and set a $83.00 price target on shares of Danaher in a research note on Tuesday, September 26th. Robert W. Baird reissued a buy rating on shares of Danaher in a research note on Friday, January 12th. Evercore ISI assumed coverage on shares of Danaher in a research note on Wednesday, January 3rd. They set an outperform rating for the company. Royal Bank of Canada reissued a hold rating and set a $96.00 price target on shares of Danaher in a research note on Thursday, January 4th. Finally, Cowen reissued a buy rating and set a $90.00 price target on shares of Danaher in a research note on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Danaher currently has an average rating of Buy and a consensus target price of $95.86.

Shares of Danaher (NYSE DHR) opened at $100.56 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.00 and a current ratio of 1.43. The firm has a market cap of $69,950.05, a P/E ratio of 29.66, a P/E/G ratio of 2.18 and a beta of 1.02. Danaher has a 12 month low of $78.97 and a 12 month high of $100.88.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Investors of record on Friday, December 29th will be issued a dividend of $0.14 per share. This represents a $0.56 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date is Thursday, December 28th. Danaher’s dividend payout ratio is currently 16.52%.

In related news, SVP Daniel Raskas sold 37,870 shares of the business’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $93.33, for a total transaction of $3,534,407.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of the company’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $92.64, for a total transaction of $11,671,620.96. Following the completion of the transaction, the chief executive officer now owns 271,737 shares of the company’s stock, valued at approximately $25,173,715.68. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 174,437 shares of company stock valued at $16,166,722. Corporate insiders own 12.20% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. GQG Partners LLC acquired a new position in shares of Danaher in the second quarter valued at approximately $101,000. Zions Bancorporation boosted its holdings in shares of Danaher by 118.3% in the third quarter. Zions Bancorporation now owns 1,231 shares of the conglomerate’s stock valued at $106,000 after buying an additional 667 shares during the period. Patten Group Inc. boosted its holdings in shares of Danaher by 262.3% in the third quarter. Patten Group Inc. now owns 4,830 shares of the conglomerate’s stock valued at $114,000 after buying an additional 3,497 shares during the period. Monetary Management Group Inc. boosted its holdings in shares of Danaher by 10.7% in the second quarter. Monetary Management Group Inc. now owns 1,550 shares of the conglomerate’s stock valued at $131,000 after buying an additional 150 shares during the period. Finally, Acrospire Investment Management LLC boosted its holdings in shares of Danaher by 185.5% in the second quarter. Acrospire Investment Management LLC now owns 1,693 shares of the conglomerate’s stock valued at $143,000 after buying an additional 1,100 shares during the period. Institutional investors own 76.12% of the company’s stock.

WARNING: “Danaher (DHR) Given “Buy” Rating at Stifel Nicolaus” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.dailypolitical.com/2018/01/22/danaher-dhr-given-buy-rating-at-stifel-nicolaus.html.

Danaher Company Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Analyst Recommendations for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.